SGLT-2 inhibitors are generally reserved as a second or third-line antihyperglycemic drug in the treatment of type 2 diabetes, but they can also be used as monotherapy when metformin is contraindicated [10]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.